Our successful story

2021

• European Commission approval for our MB02 bevacizumab. Launched across a multiple markets in Europe.
• Manufacture of the AstraZeneca/Oxford Covid19 Vaccine.
2020

• New state-of-the-art mAbxience biomanufacturing facility opening in Argentina.
• MB02 Bevacizumab Global regulatory submission.
• Commercial presence via B2B partners in more than 100 markets.
• 3 years of recognized safety standard OHSAS 18001:2007 Certification.
2019

• New partnerships in EU, Japan, Russia, Canada and other key markets.
• Partnered worlwide with MB02 bevacizumab biosimilar.
2018

• Alliances with leading pharma companies in EU, USA, and Australia.
• “Business Development of the Year” Award 2018 by GGBA.
2017

• EMA GMP certification granted to mAbxience Spain.
• First successful Scientific Advices with EMA and FDA.
• Expansion of global access of MB01 rituximab & MB02 bevacizumab.
2016

• First launch of MB02 bevacizumab (Bevax®, Argentina).
• “Biosimilar Initiative of the Year” Award 2016 by GGBA.
• Global consortium established for the development of MB05 palivizumab*.
2015

• mAbxience Spain biomanufacturing and R&D center: inauguration.
2014

• Acquisition of Genhelix, a Spanish biotech R&D center becoming mAbxience scientific and operational hub.
• First launch of MB01 rituximab (Novex®, Argentina).
2012

• mAbxience Argentina biomanufacturing facility: inauguration.
2010

• Established in Europe.
• Acquisition of PharmaADN: mAbxience Argentina R&D platform.